Our Purpose
Chronic Liver Disease (CLD) is a major global health challenge and a leading cause of morbidity and mortality worldwide. The most common causes of chronic liver disease include viral hepatitis, specifically hepatitis B, C, and D, alcohol-related liver disease, metabolic dysfunction–associated steatotic liver disease (MASLD/MASH), and autoimmune liver diseases such as primary biliary cholangitis (PBC). Despite significant advances in medical science, CLD continues to impose a substantial clinical, economic, and societal burden, with marked regional variation in prevalence, disease progression, access to care, and patient outcomes.
Understanding the true global impact of chronic liver disease requires international collaboration and region-specific insights. The Global Liver Council™ (GLC) was established to bring together leading experts from across the world who share a commitment to advancing knowledge and improving outcomes in chronic liver diseases. By fostering collaboration and the exchange of perspectives across regions, the GLC seeks to address unmet needs and inform strategies that reflect real-world clinical practice and patient experience.
The Global Liver Council™
The Global Liver Council ™ is an international, multidisciplinary consortium of recognized experts in hepatology, gastroenterology, and liver-related research. The Council was formed to promote collaboration, dialogue, and innovation in the fields of viral hepatitis, alcohol-related liver disease, and autoimmune cholestatic disorders, including primary biliary cholangitis.
Given the global distribution and heterogeneity of chronic liver diseases (CLDs), the Global Liver Council™ places strong emphasis on incorporating regional perspectives when assessing the clinical and economic impact of CLD. The Council provides a platform for experts from different healthcare systems and geographic regions to share insights based on local realities, ensuring that research and discussions are globally relevant and clinically meaningful.
The Global Liver Council™ (GLC) works closely with the Global NASH/MASH Council™ (GNC), which comprises more than 338 experts from 66 countries. Through this collaboration, GLC members engage in regular virtual scientific meetings and convene in-person meetings when needed. These meetings are designed to address emerging topics in specific areas of chronic liver disease, including alcohol-related liver disease, hepatitis D virus infection and primary biliary cholangitis, and to develop joint research initiatives that advance understanding of disease burden and patient impact.
In addition, Council members form focused collaborative teams to address specific unmet needs, such as evaluating region-specific patient-reported outcomes and understanding variations in disease experience and management. Many members of the Global Liver Council™ also serve as active participating sites for the Global Liver Registry™, further strengthening the integration between expert collaboration and real-world data generation.
Learn More
The Global Liver Registries
The Global Liver Registry™ is a multinational collaborative initiative led by members of the Global Liver Council™ in partnership with the Global NASH/MASH Council™. The Registry was established to collect high-quality real-world clinical data, laboratory data, and patient-reported outcomes from individuals with the most common causes of chronic liver disease, including MASLD/MASH, viral hepatitis B, C, and D, primary biliary cholangitis, and alcohol-related liver disease.
Participation in the Global Liver Registry™ requires ethics committee approval, and all data are entered through a secure, cloud-based platform into a centralized database managed by a dedicated data management team. All information is fully de-identified and compliant with HIPAA and applicable international data protection standards. Registry sites span North America, Europe, Asia, the Middle East, North Africa, and Australia, enabling meaningful cross-regional analyses.
The overarching goal of the Global Liver Registry™ is to generate robust real-world evidence that enhances understanding of disease patterns, clinical practice, and patient-reported experiences across different regions of the world. By capturing similarities and differences in chronic liver disease across diverse populations, the Registry aims to inform research, guide clinical decision-making, and support efforts to improve outcomes for patients globally.
Learn More